[HTML][HTML] Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma
…, WF Li, YH Li, LL Tang, YP Mao, GQ Zhou… - … England Journal of …, 2019 - Mass Medical Soc
Background Platinum-based concurrent chemoradiotherapy is the standard of care for patients
with locoregionally advanced nasopharyngeal carcinoma. Additional gemcitabine and …
with locoregionally advanced nasopharyngeal carcinoma. Additional gemcitabine and …
The molecular biology of pancreatic adenocarcinoma: Translational challenges and clinical perspectives
…, L Zhu, XQ Zhu, ZF Wang, XL Wu, CH Zhou… - Signal transduction and …, 2021 - nature.com
Pancreatic cancer is an increasingly common cause of cancer mortality with a tight correspondence
between disease mortality and incidence. Furthermore, it is usually diagnosed at an …
between disease mortality and incidence. Furthermore, it is usually diagnosed at an …
[HTML][HTML] Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations
…, WK Shi, ML Li, JJ Zhu, CJ Tan, ZY Tang, J Zhou… - Liver cancer, 2021 - karger.com
Background: Combined therapy with tyrosine kinase inhibitors (TKIs) and anti-PD-1
antibodies has shown high tumor response rates for patients with unresectable hepatocellular …
antibodies has shown high tumor response rates for patients with unresectable hepatocellular …
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised …
YP Chen, X Liu, Q Zhou, KY Yang, F Jin, XD Zhu, M Shi… - The Lancet, 2021 - thelancet.com
Background Patients with locoregionally advanced nasopharyngeal carcinoma have a high
risk of disease relapse, despite a high proportion of patients attaining complete clinical …
risk of disease relapse, despite a high proportion of patients attaining complete clinical …
XTH31, Encoding an in Vitro XEH/XET-Active Enzyme, Regulates Aluminum Sensitivity by Modulating in Vivo XET Action, Cell Wall Xyloglucan Content, and Aluminum Binding …
… Yi Hua Zhou , Yi Hua Zhou … Fry, Bao Cai Zhang, Yi Hua Zhou, Janet Braam, Tao Jiang, Xiao
Yan Xu, Chuan Zao Mao, Yuan Jiang Pan, Jian Li Yang, Ping Wu, Shao Jian Zheng, XTH31, …
Yan Xu, Chuan Zao Mao, Yuan Jiang Pan, Jian Li Yang, Ping Wu, Shao Jian Zheng, XTH31, …
Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer's disease
Amyloid-beta (Aβ) plays a pivotal role in the pathogenesis of Alzheimer’s disease (AD). The
physiological capacity of peripheral tissues and organs in clearing brain-derived Aβ and its …
physiological capacity of peripheral tissues and organs in clearing brain-derived Aβ and its …
[HTML][HTML] Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)
HC Sun, J Zhou, Z Wang, X Liu, Q Xie… - … surgery and nutrition, 2022 - ncbi.nlm.nih.gov
Recent advances in systemic and locoregional treatments for patients with unresectable or
advanced hepatocellular carcinoma (HCC) have resulted in improved response rates. This …
advanced hepatocellular carcinoma (HCC) have resulted in improved response rates. This …
Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation
…, Y Huang, JH Huang, P Sun, NN Zhou… - Nature …, 2020 - nature.com
Most triple-negative breast cancer (TNBC) patients fail to respond to T cell-mediated
immunotherapies. Unfortunately, the molecular determinants are still poorly understood. Breast …
immunotherapies. Unfortunately, the molecular determinants are still poorly understood. Breast …
FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer
…, KM Zhang, J Mai, BX Hu, JH Huang, LH Zhou… - Nature …, 2021 - nature.com
Most patients with triple negative breast cancer (TNBC) do not respond to anti-PD1/PDL1
immunotherapy, indicating the necessity to explore immune checkpoint targets. B7H3 is a …
immunotherapy, indicating the necessity to explore immune checkpoint targets. B7H3 is a …
A review of recent developments in the surface modification of LiMn2O4 as cathode material of power lithium-ion battery
TF Yi, YR Zhu, XD Zhu, J Shu, CB Yue, AN Zhou - Ionics, 2009 - Springer
LiMn 2 O 4 (LMO) is a very attractive choice as cathode material for power lithium-ion
batteries due to its economical and environmental advantages. However, LiMn 2 O 4 in the 4-V …
batteries due to its economical and environmental advantages. However, LiMn 2 O 4 in the 4-V …
